Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Myocardial Ischemia Pipeline Drugs Market Overview
Myocardial ischemia pipeline market research report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.
Key Targets in the Myocardial Ischemia Pipeline Market
The key targets in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5, Fibroblast Growth Factor 4, Gap Junction Alpha 1 Protein, N-Formyl Peptide Receptor 2, N-Formyl Peptide Receptor 3, Nitric Oxide Synthase Inducible, Protein Phosphatase 2A, Receptor Type Tyrosine Protein Phosphatase S, Transient Receptor Potential Cation Channel Subfamily M Member 7, and Vascular Endothelial Growth Factor A.
Key MoA in the Myocardial Ischemia Pipeline Market
The key MoA in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5 Inhibitor, Fibroblast Growth Factor 4 Activator, Gap Junction Alpha 1 Protein Inhibitor, N-Formyl Peptide Receptor 2 Agonist, N-Formyl Peptide Receptor 3 Agonist, Nitric Oxide Synthase Inducible Inhibitor, Protein Phosphatase 2A Inhibitor, Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Transient Receptor Potential Cation Channel Subfamily M Member 7 Blocker, and Vascular Endothelial Growth Factor A Activator.
Key RoA in the Myocardial Ischemia Pipeline Market
The key RoA in the myocardial ischemia pipeline market are oral, intracardiac, intracoronary, intradermal, intravenous, parenteral, and topical. Oral has the highest number of pipeline products.
Myocardial Ischemia Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Myocardial Ischemia Pipeline Market
The key molecule types in the myocardial ischemia pipeline market are small molecule, recombinant protein, gene therapy, peptide, synthetic peptide, cell therapy, and oligonucleotide. Small molecule has the highest number of pipeline products.
Myocardial Ischemia Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Myocardial Ischemia Pipeline Market
The key companies in the myocardial ischemia pipeline market are Anagenics Ltd, Angionetics Inc, AstraZeneca Plc, BioCardia Inc, Chrysalis BioTherapeutics Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd.
Market report overview
Key targets | Adenylate Cyclase Type 5, Fibroblast Growth Factor 4, Gap Junction Alpha 1 Protein, N-Formyl Peptide Receptor 2, N-Formyl Peptide Receptor 3, Nitric Oxide Synthase Inducible, Protein Phosphatase 2A, Receptor Type Tyrosine Protein Phosphatase S, Transient Receptor Potential Cation Channel Subfamily M Member 7, and Vascular Endothelial Growth Factor A |
Key MoA | Adenylate Cyclase Type 5 Inhibitor, Fibroblast Growth Factor 4 Activator, Gap Junction Alpha 1 Protein Inhibitor, N-Formyl Peptide Receptor 2 Agonist, N-Formyl Peptide Receptor 3 Agonist, Nitric Oxide Synthase Inducible Inhibitor, Protein Phosphatase 2A Inhibitor, Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Transient Receptor Potential Cation Channel Subfamily M Member 7 Blocker, and Vascular Endothelial Growth Factor A Activator |
Key RoA | Oral, Intracardiac, Intracoronary, Intradermal, Intravenous, Parenteral, and Topical |
Key molecule types | Small Molecule, Recombinant Protein, Gene Therapy, Peptide, Synthetic Peptide, Cell Therapy, and Oligonucleotide |
Key companies | Anagenics Ltd, Angionetics Inc, AstraZeneca Plc, BioCardia Inc, Chrysalis BioTherapeutics Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Angionetics Inc
AstraZeneca Plc
BioCardia Inc
Chrysalis BioTherapeutics Inc
CohBar Inc
Eight Plus One Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Imbria Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
NervGen Pharma Corp
NoNO Inc
Omniox Inc
Q BioMed Inc
Symvivo Inc
Vasade Biosciences Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the myocardial ischemia pipeline market?
The key targets in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5, Fibroblast Growth Factor 4, Gap Junction Alpha 1 Protein, N-Formyl Peptide Receptor 2, N-Formyl Peptide Receptor 3, Nitric Oxide Synthase Inducible, Protein Phosphatase 2A, Receptor Type Tyrosine Protein Phosphatase S, Transient Receptor Potential Cation Channel Subfamily M Member 7, and Vascular Endothelial Growth Factor A.
-
What are the key MoA in the myocardial ischemia pipeline market?
The key MoA in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5 Inhibitor, Fibroblast Growth Factor 4 Activator, Gap Junction Alpha 1 Protein Inhibitor, N-Formyl Peptide Receptor 2 Agonist, N-Formyl Peptide Receptor 3 Agonist, Nitric Oxide Synthase Inducible Inhibitor, Protein Phosphatase 2A Inhibitor, Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Transient Receptor Potential Cation Channel Subfamily M Member 7 Blocker, and Vascular Endothelial Growth Factor A Activator.
-
What are the key RoA in the myocardial ischemia pipeline market?
The key RoA in the myocardial ischemia pipeline market are oral, intracardiac, intracoronary, intradermal, intravenous, parenteral, and topical.
-
What are the key molecule types in the myocardial ischemia pipeline market?
The key molecule types in the myocardial ischemia pipeline market are small molecule, recombinant protein, gene therapy, peptide, synthetic peptide, cell therapy, and oligonucleotide.
-
What are the key companies in the myocardial ischemia pipeline market?
The key companies in the myocardial ischemia pipeline market are Anagenics Ltd, Angionetics Inc, AstraZeneca Plc, BioCardia Inc, Chrysalis BioTherapeutics Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.